Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2018 | Therapeutically targeting mutations in myeloma: NF-κB, t(4;14) and BRAF

As our knowledge of the genetics of multiple myeloma (MM) advances, we can more precisely understand and target the disease. Here, Martin Kaiser, MD, of the Institute of Cancer Research, London, UK, discusses how different classes of genetic abnormalities in MM could be targeted. Dr Kaiser highlights exciting work on the t(4;14) translocation in MM and tissue agnostic therapies.This video was recorded at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.